Nile Therapeutics has completed the dose escalation stage of an ongoing Phase II study of CD-NP in patients with acute decompensated heart failure.

Nile said it reached a maximum tolerated dose in the patient population through the NIL-CDNP-CT005 study and identified two doses that suit safety and activity profile in acute heart failure patients.

CD-NP is a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure

Of the 75 patients intended for inclusion in the study, 52 patients have been enrolled and the study data will be available late this year.